Background {#Sec1}
==========

Invasive micropapillary carcinoma (IMPC) of the breast is an uncommon variant of breast cancer that was first described in 1980 \[[@CR1]\]. Histologically, this subtype appears as tumor cells arranged in small solid fragments or tubules with small or obliterated lumina, which appear as micropapillae without central fibrovascular cores \[[@CR2]\]. These micropapillae are surrounded by clear stromal spaces not lined by endothelial cells, giving it an appearance similar to retraction artifact \[[@CR3]\]. IMPC constitutes less than 2% of all invasive breast cancers, although 3%--6% of invasive breast cancers were reported to have a focal micropapillary growth pattern \[[@CR4]\].

Previous studies demonstrated that IMPC was associated with lymphovascular invasion and a higher propensity for lymph node metastases than invasive ductal carcinoma (IDC) and other invasive subtypes of breast cancer \[[@CR5]--[@CR8]\]. It has been thought that, due to the lymphotropic nature of IMPC, these patients experience worse overall outcomes than those with IDC. The National Cancer Database (NCDB) is a national hospital-based cancer registry that is co-sponsored by the American College of Surgeons (ACoS) and the American Cancer Society. It houses data from more than 1500 hospitals with ACoS-accredited cancer treatment programs, accounting for almost 70% of all newly diagnosed cancer cases in the United States \[[@CR9]--[@CR14]\]. In this study, we aimed to analyze the survival outcomes of IMPC patients recorded in the NCDB.

Patients and methods {#Sec2}
====================

Patient selection {#Sec3}
-----------------

Records of patients with biopsy-proven IMPC diagnosed between January 2004 and December 2014 were retrieved from the NCDB. Diagnosis was made according to the International Classification of Disease for Oncology, third edition (ICD-O-3), code 8507. This study only included patients with American Joint Committee on Cancer (AJCC, 7th edition) stage cT1-4N0-3M0 pure IMPC and complete records regarding surgical therapy and radiotherapy.

Prognosis analysis {#Sec4}
------------------

Data of patient's age, race, sex, Charlson--Deyo comorbidity score, histologic grade, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status (only available for patients diagnosed between 2010 and 2014), TNM stage, number of positive lymph nodes, type of surgical resection, and the receipt of external beam radiotherapy (EBRT), chemotherapy, and hormonal therapy were collected.

Univariate analysis evaluated factors associated with overall survival (OS); subsequently, Cox multivariate analysis included variables that were statistically significant with a *P* value of \< 0.05. OS was defined as the duration from the date of diagnosis to the date of last follow-up and was assessed using the Kaplan--Meier method. Patients were censored at the data of either death or the last follow-up. Only patients with complete data for the parameters of interest were included in the final analysis. Statistical analyses were performed using Stata/SE version 10 for Windows (StataCorp, College Station, TX, USA). A *P* value \< 0.05 was considered significant.

Results {#Sec5}
=======

Patient characteristics {#Sec6}
-----------------------

Overall, as shown in Fig. [1](#Fig1){ref-type="fig"}, a total of 2660 patients met the selection criteria. Median follow-up was 40 months (range 0.5--137 months). The median age of diagnosis was 60 years (range 19--90 years). Complete patient characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Fig. 1Diagram of selecting records of patients with invasive micropapillary breast cancer from the National Cancer Database Table 1Characteristics of the 2660 patients with invasive micropapillary breast cancerCharacteristicAll patients \[cases (%)\]Total2660Age ≤ 50 years564 (21.2) 51--64 years1031 (38.8) ≥ 65 years1065 (40.0)Race White2169 (81.5) African American351 (13.2) Others140 (5.3)Sex Female2607 (98.0) Male53 (2.0)Charlson--Deyo comorbidity score 02210 (83.1) 1362 (13.6) ≥ 288 (3.3)Clinical T stage T11655 (62.2) T2738 (27.7) T3184 (6.9) T483 (3.1)Clinical N stage N01998 (75.1) N1532 (20.0) N281 (3.0) N349 (1.8)Surgery Lumpectomy1281 (48.2) Mastectomy1379 (51.8)Lymph nodes involved 01243 (46.7) 1--3689 (25.9) ≥ 4501 (18.8) Unknown227 (8.5)Histologic grade^a^ 1196 (7.4) 21333 (50.1) 3971 (36.5) Not reported160 (6.0)ER status Positive2327 (87.5) Negative291 (10.9) Unknown42 (1.6)PR status Positive2112 (79.4) Negative498 (18.7) Unknown50 (1.9)HER2 status Positive397 (14.9) Negative1498 (56.3) Unknown765 (28.8)Tumor markers ER+ HER2−1402 (52.7) ER+ HER2+297 (11.2) ER− HER2+99 (3.7) ER− HER2−95 (3.6) Not reported767 (28.8)Radiotherapy Yes1592 (59.8) No1068 (40.2)Chemotherapy Yes1273 (47.9) No1024 (38.5) Not reported363 (13.6)Hormonal therapy Yes1979 (74.4) No501 (18.8) Not reported180 (6.8)*ER* estrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2^a^Well, moderately, and poorly differentiated/undifferentiated tumors were classified into histologic grades 1, 2, and 3, respectively

At presentation, 662 (24.9%) patients had nodal involvement. In terms of histologic grade, 2304 (86.6%) patients had grade 2 or 3 disease, only 196 (7.4%) patients had grade 1 disease. In terms of biomarker status, 2327 (87.5%) had ER-positive disease, 2112 (79.4%) had PR-positive disease, and 397 (14.9%) had HER2-positive disease. Unfortunately, 765 (28.8%) patients had unknown HER2 status. Of the patients with complete biomarker status, a majority had hormone receptor-positive, HER2-negative disease.

In terms of surgery, 1281 (48.2%) patients underwent lumpectomy, and 1379 (51.8%) underwent mastectomy. Overall, 1592 (59.9%) patients received EBRT, 1979 (74.4%) received hormonal therapy, and 1273 (47.9%) received chemotherapy.

Outcomes and prognostic factors {#Sec7}
-------------------------------

At a median follow-up of 4 years (interquartile range 3.2--7.4 years), the 5-year OS rate was 87.5% (95% confidence interval \[CI\] 85.6%--89.4%). Univariate analysis showed that patients with ≥ 4 positive lymph nodes had shorter OS than patients with node-negative disease (hazard ratio \[HR\], 2.44; 95% CI 1.75--3.40; *P* \< 0.001). However, those with 1--3 positive nodes had an OS similar to patients with node-negative disease (Fig. [2](#Fig2){ref-type="fig"}). As presented in Table [2](#Tab2){ref-type="table"}, other indicators of poor prognosis on univariate analysis included age ≥ 65 years (HR, 1.93; 95% CI 1.33--2.81; *P* = 0.001), Charlson--Deyo comorbidity score = 1 (HR, 1.87; 95% CI 1.31--2.67; *P* = 0.001), Charlson--Deyo comorbidity score ≥ 2 (HR, 3.35; 95% CI 1.90--5.91; *P* \< 0.001), omission of radiotherapy (HR, 1.76; *P* \< 0.001), mastectomy (HR, 1.37; 95% CI 1.04--1.81; *P* = 0.025), ER-negative disease (HR, 2.24; 95% CI 1.63--3.11; *P* \< 0.001), and lack of hormonal therapy use (HR, 1.53; 95% CI 1.13--2.05; *P* = 0.005). On multivariate analysis, factors associated with short OS included age \> 65 years, Charlson--Deyo comorbidity score of 1 or ≥ 2, stage T2--4, stage N2, omission of radiation therapy, ER-negative disease, PR-negative disease, or ≥ 4 metastatic lymph nodes (*P* \< 0.05 for all).Fig. 2Kaplan--Meier overall survival curves of patients with invasive micropapillary breast cancer stratified by number of positive lymph nodes Table 2Prognostic factors for overall survival of patients with invasive micropapillary breast cancerCharacteristicUnivariate analysisMultivariate analysisHR95% CI*P* valueHR95% CI*P* valueAge ≤ 501.0001.000 51--640.7830.515--1.1930.2550.8990.585--1.3820.628 ≥ 651.9291.327--2.8050.0012.4941.657--3.752\< 0.001Race White1.000------ African American1.0010.667--1.5030.995------ Other0.5910.277--1.2570.172------Sex Female1.000------ Male1.1300.465--2.7400.787------Charlson--Deyo comorbidity score 01.0001.000 11.8711.311--2.6710.0011.5131.049--2.1830.027 ≥ 23.3491.898--5.910\< 0.0012.2001.217--3.9780.009Clinical T stage 11.0001.000 22.0521.507--2.794\< 0.0011.8881.340--2.660\< 0.001 32.3451.504--3.656\< 0.0012.2301.314--3.7840.003 43.6492.222--5.993\< 0.0012.8511.602--5.073\< 0.001Clinical N stage 01.0001.000 11.5461.122--2.1300.0081.1940.771--1.8500.426 23.8322.390--6.147\< 0.0012.0091.099--3.6760.024 31.8250.852--3.9080.1220.9250.292--2.1840.859Surgery Lumpectomy1.0001.000 Mastectomy1.3731.040--1.8120.0251.0270.751--1.4040.869Radiotherapy Yes1.0001.000 No1.7551.336--2.307\< 0.0012.3441.711--3.210\< 0.001Histologic grade Well differentiated1.000------ Moderately differentiated0.9810.558--1.7230.946------ Poorly differentiated/undifferentiated1.4570.831--2.5520.189------ Not reported0.7210.291--1.7880.481------ER status Positive1.0001.000 Negative2.2451.629--3.113\< 0.0012.8041.827--4.305\< 0.001 Unknown0.7040.260--1.9060.4900.5850.211--1.6260.304PR status Positive1.0001.000 Negative1.65011.223--2.2270.0011.5861.166--2.1560.003 Unknown0.7310.298--1.7880.4920.8250.335--2.0450.677HER2 status Positive1.000------ Negative1.0210.604--1.7280.937------ Unknown0.8570.503--1.4600.570------Chemotherapy Yes1.000------ No0.9140.679--1.2300.552------ Not reported1.3140.874--1.9770.189------Hormonal therapy Yes1.0001.000 No1.5261.134--2.0540.0050.7890.538--1.1580.227 Not reported1.2960.745--0.2540.3581.0130.567--1.8100.965Lymph nodes involved 01.0001.000 1--30.9710.656--1.4380.8831.0870.700--1.6870.711 4 or more2.4381.750--3.398\< 0.0012.2921.413--3.7190.001 Unknown1.8231.174--0.8280.0071.5070.962--2.3610.073*OS* overall survival, *HR* hazard ratio, *CI* confidence interval, *ER* estrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2

Figure [3](#Fig3){ref-type="fig"} represents Kaplan--Meier curves comparing overall survival of patients who underwent surgery either with or without radiotherapy. A longer OS was associated with radiotherapy among patients receiving lumpectomy, but such association was not observed among patients with either positive or negative nodal disease receiving mastectomy.Fig. 3Kaplan--Meier overall survival curves of patients who underwent surgery with or without external beam radiotherapy. **a** Patients receiving lumpectomy; **b** patients with negative lymph nodes receiving mastectomy; and **c** patients with positive lymph nodes receiving mastectomy

Discussion {#Sec8}
==========

IMPC is a rare variant of breast cancer, making it difficult to study. As a result, using a large national database such as the NCDB allows for analysis using a large number of patients to help inform treatment management decisions. Our findings indicated that EBRT was associated with prolonged OS in IMPC patients undergoing lumpectomy but not for patients undergoing mastectomy. Additional poor prognostic factors for OS included older age, extensive lymph node involvement, and ER-positive disease.

The findings of this study are in accordance with those in the literature (Table [3](#Tab3){ref-type="table"}) in that there is a higher rate of lymph node involvement seen in IMPC compared to the rate seen in IDC in previous studies. Because a higher rate of lymph node involvement and/or higher number of metastatic lymph nodes confers a higher N stage, it has been presumed that IMPC patients have worse survival outcomes than IDC patients. However, despite this higher propensity for lymph node involvement with IMPC than with IDC, we found that the 5-year OS rate of IMPC patients in our analysis was similar to the historical 5-year OS rate of patients with IDC reported in previous literature, which is in accordance with an analysis of a large group of IMPC patients using the Surveillance, Epidemiology, and End Results (SEER) database \[[@CR3], [@CR15]\].Table 3Literature review on invasive micropapillary carcinoma of the breastStudyCasesAge (years)^a^ER+ (%)PR+ (%)HER2+ (%)RLN+ (%)DSS (%)OS (%)Follow-up duration^a^NCDB (current study)18186084.373.919.455.2--87.5 at 5 years4 yearsKim et al. \[[@CR2]\]3847.319.419.4--78.9------Chen et al. \[[@CR3]\]62461.784.869.9--52.992 at 5 years84 at 5 years33.0 monthsYu et al. \[[@CR5]\]2674766.366.328.862.9--97.7 at 5 years59 monthsChen et al. \[[@CR6]\]9558.983.274.721.172.6--81.9 at 5 years60 monthsShi et al. \[[@CR7]\]18852.785.178.229.973.475.9 at 5 years--40.5 monthsCui et al. \[[@CR8]\]2552.38864--80----36.5 monthsWalsh & Bleiweiss \[[@CR37]\]8058.890.670.359.172.3------Vingiani et al. \[[@CR38]\]4952.787.869.418.469.4--89.8 at 6 years6 yearsAdrada et al. \[[@CR39]\]2956^a^82614362------Chen et al. \[[@CR40]\]100504627--84.863.359 at 5 years60.1 monthsDe La Cruz et al. \[[@CR41]\]1650.95031.25092.9--7538 monthsLuna-Moré et al. \[[@CR42]\]6854.374.546.3--90.5--6352.6 monthsMiddleton et al. \[[@CR43]\]14502512.5----70 at 5 years--57.6 monthsNassar et al. \[[@CR44]\]836171----7740467 yearsPaterakos et al. \[[@CR45]\]185561.1\< 50--95.2--50 at 44 months165.6 monthsPettinato et al. \[[@CR46]\]62573220959049--5.2 yearsYamaguchi et al. \[[@CR47]\]1560.1736733.346.6------Zekioglu et al. \[[@CR48]\]5352.56861--68.8--7256.5 months*ER* estrogen receptor, *+* positivity, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2, *RLN* regional lymph node metastasis, *DSS* disease-specific survival, *OS* overall survival, *NCDB* National Cancer Database, -- not available or not reported^a^Median or mean age

The IMPC patient characteristics in the present study differ in some ways from the IMPC patient characteristics reported in the literature. For example, the median age of presentation for IMPC patients, while similar to the SEER database analysis \[[@CR3], [@CR15]\], was older than the age at presentation reported in other IMPC patient series \[[@CR2], [@CR3], [@CR5], [@CR6]\]. In addition, we found higher rates of hormone receptor positivity than the rates in those series. As we know, ER positivity is associated with older age and longer OS of breast cancer patients as a whole \[[@CR16], [@CR17]\], which may explain the favorable survival outcomes for IMPC patients in the present study.

On multivariate analysis, ER positivity was associated with improved prognosis. This finding speaks to the growing focus in oncology on the molecular and biologic characteristics of disease rather than the clinical presentations and stage. The majority of patients in our analysis fall under the luminal A/B molecular subtypes (hormone receptor-positive, HER2-negative), which are associated with better outcomes than HER2-positive or triple-negative disease \[[@CR18]--[@CR20]\].

It is interesting to note that age \< 50 years was associated with prolonged OS, as it has been previously observed that breast cancer patients who present at a younger age tend to have worse outcomes \[[@CR21]--[@CR23]\]. This finding may be unique to this particular subtype of breast cancer although several contributing and confounding factors may also be at play. In breast cancer as a whole, patients who present at a younger age are more likely to have more aggressive molecular subtypes, higher grade disease, and present at a more advanced stage than those at an older age \[[@CR24]--[@CR26]\]. As noted previously, the large majority of IMPC patients in our analysis had high rates of ER and PR positivity and therefore fall under the luminal A and B molecular subtypes, which may explain why the younger patients in our study did not have a worse prognosis. In addition, because the NCDB tracks only OS and not cause-specific or disease-specific survival, it is possible that patients older than 50 years had other comorbidities that affected the survival outcomes. Indeed, a Charlson--Deyo comorbidity score ≥ 1 was associated with short OS of IMPC patients on both univariate and multivariate analyses, which is consistent with the observations on breast cancer as a whole \[[@CR27]--[@CR29]\].

Another important and interesting finding of our analysis is that EBRT was associated with prolonged OS on univariate analysis. Importantly, the OS benefit was limited to patients receiving lumpectomy, and no OS benefit was observed among patients receiving mastectomy. Radiotherapy is well known to improve locoregional control and OS after breast-conserving surgery and mastectomy \[[@CR30]--[@CR33]\], but has not been studied specifically in IMPC. It is possible that, due to the high propensity of lymph node involvement in IMPC, EBRT may be important to provide good locoregional control and, subsequently, OS.

For breast cancer as a whole, the role of EBRT in nodal disease has evolved over time \[[@CR28]\]. Given IMPC's lymphotrophic nature, whether regional nodes should be included along with the standard whole-breast irradiation field is an important issue. Recent trials have highlighted prolonged disease-free survival with regional nodal irradiation (RNI) in patients with early-stage breast cancer \[[@CR34], [@CR35]\]. In addition, a meta-analysis conducted by the Early Breast Cancer Trialists' Collaborative Group demonstrated that the survival benefit of postmastectomy radiotherapy with comprehensive lymph node coverage is not limited to patients with ≥ 4 positive lymph nodes, but also extended to patients with 1--3 positive lymph nodes \[[@CR36]\]. Although EBRT likely plays an important part in the treatment of IMPC, the specific role of RNI in this subtype is still unclear.

Our study has several limitations due to its reliance on the NCDB. First, the retrospective nature of the study and all associated inherent biases must be acknowledged. The lack of central review of pathology specimens is another limitation; it is not clear what threshold level of micropapillary involvement was required for the samples to be flagged as IMPC in the database. However, previous studies have failed to find an association between the degree of micropapillary involvement and OS or lymph node involvement, suggesting that the presence of IMPC involvement (not the degree of involvement) is the most important factor in determining outcomes \[[@CR2], [@CR37]\]. The NCDB also does not include information of the receipt of targeted therapy. Finally, although the NCDB has information regarding the treatment delivered, it does not have information regarding the reasons for the delivery of each treatment. It is possible that patients who did not receive radiotherapy may have had a low Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status (KPS) score, and that the observed short OS in these patients was likely due to their underlying poor performance status and not the omission of radiotherapy.

Conclusions {#Sec9}
===========

Although IMPC has a high propensity for lymph node metastasis, patients' OS is comparable to the historical OS of IDC reported in literature. On univariate analysis, ≥ 4 positive lymph nodes, a Charlson--Deyo comorbidity score ≥ 1, and age \> 65 years were associated with short OS. In contrast, receipt of EBRT and ER positivity were associated with prolonged OS. This study demonstrated a survival benefit of IMPC patients associated with EBRT, though this may be limited to patients receiving lumpectomy.
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